The calcineurin-NFAT pathway and bone: Intriguing new findings

Molecular Interventions

Volumn 6, Issue 4, 2006, Pages 193-196

  Stern, Paula H ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CHEMOKINE; FRIZZLED PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; SMAD PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; WNT PROTEIN;

CELL DIFFERENTIATION; CELL PROLIFERATION; COLLAGEN SYNTHESIS; DRUG EFFECT; GENE EXPRESSION; HUMAN; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW;

ANIMALS; BONE RESORPTION; CALCINEURIN; CYCLOSPORINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NFATC TRANSCRIPTION FACTORS; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; SIGNAL TRANSDUCTION;

EID: 33749025045     PISSN: 15340384     EISSN: None     Source Type: Journal    
DOI: 10.1124/mi.6.4.4     Document Type: Review

References (32)

1. Boise, L.H., Petryniak, B., Mao, X. et al. The NFAT-1 DNA binding complex in activated T cells contains Fra-1 and JunB. Mol. Cell. Biol. 13, 1911-1199 (1993).
2. Verweij, C.L., Guidos, C., and Crabtree, G.R. Cell type specificity and activation requirements for NFAT-1 (nuclear factor of activated T-cells) transcriptional activity determined by a new method using transgenic mice to assay transcriptional activity of an individual nuclear factor. J. Biol. Chem. 265, 15788-15795 (1990).
3. Cockerill, P.N., Shannon, M.F., Bert, A.G., Ryan, G.R., and Vadas, M.A. The granulocyte/macrophage colony-stimulating factor/interleukin 3 locus is regulated by an inducible cyclosporin A-sensitive enhancer. Proc. Natl. Acad. Sci. U.S.A. 90, 2466-2470 (1993).
4. Todd, M.D., Grusby, M.J., Lederer, J.A., Lacy, E., Lichtman, A.H., and Glimcher, L.H. Transcription of the interleukin 4 gene is regulated by multiple promoter elements. J. Exp. Med. 177, 1663-7164 (1993).
5. Stranick, K.S., Payvandi, F., Zambas, D.N., Umland, S.P., Egan, R.W., Billah, M.M. Transcription of the murine interleukin 5 gene is regulated by multiple promoter elements. J. Biol. Chem. 270, 20575-20582 (1995).
6. Tsuboi, A., Masuda, E.S., Naito, Y., Tokumitsu, H., Arai, K., and Arai, N. Calcineurin potentiates activation of the granulocyte-macrophage colony-stimulating factor gene in T cells: Involvement of the conserved lymphokine element 0. Mol. Biol. Cell 5, 119-128 (1994).
7. Goldfeld, A.E., McCaffrey, P.G., Strominger, J.L., and Rao, A. Identification of a novel cyclosporin-sensitive element in the human tumor necrosis factor alpha gene promoter. J. Exp. Med. 178, 1365-1379 (1993).
8. Crabtree, G.R. and Olson, E.N. NFAT signaling: Choreographing the social lives of cells. Cell 109 Suppl, S67-S79 (2002).
9. Horsley, V. and Pavlath, G.K. NFAT: Ubiquitous regulator of cell differentiation and adaptation. J. Cell Biol. 156, 771-774 (2002).
10. de la Pompa, J.L., Timmerman, L.A., Takimoto, H. et al. Role of the NF-ATc transcription factor in morphogenesis of cardiac valves and septum. Nature 392, 182-186 (1998).
11. Ranger, A.M., Grusby, M.J., Hodge, M.R., Gravallese, E.M., de la Brousse, F.C., Hoey, T., Mickanin, C., Baldwin, H.S., and Glimcher, L.H. The transcription factor NF-ATc is essential for cardiac valve formation. Nature 392, 186-190 (1998).
12. 2+/calcineurin and NFATc3/c4 pattern the developing vasculature. Cell 105, 863-875 (2001).
13. Hernandez, G.L., Volpert, O.V., Iniguez, M.A., Lorenzo, E., Martinez-Martinez, S., Grau, R., Fresno, M., and Redondo, J.M. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: Roles of the nuclear factor of activated T cells and cyclooxygenase 2. J. Exp. Med. 193, 607-620 (2001).
14. Neal, J.W. and Clipstone, N.A. A constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblasts. J. Biol. Chem. 278, 17246-17254 (2003).
15. Clipstone, N.A. and Crabtree, G.R. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 357, 695-697 (1992).
16. Koga, T., Matsui, Y., Asagiri, M., Kodama, T., de Crombrugghe, B., Nakashima, K., and Takayanagi, H. NFAT and Osterix cooperatively regulate bone formation. Nat. Med. 11, 880-885 (2005). This study provides evidence for a role of NFAT in osteoblast differentiation and a mechanism for the effect. Overexpression of NFATc1 in calvarial osteoblast precursor cells stimulated activation of the gene encoding the type I collagen promoter through the zinc-finger transcription factor Osterix, but not through Runx-2 or BMP-2.
17. Winslow, M.M., Pan, M., Starbuck, M., Gallo, E.M., Deng, L., Karsenty, G., and Crabtree, G.R. Calcineurin/NFAT signaling in osteoblasts regulates bone mass. Dev. Cell 10, 771-782 (2006). This study showed effects of NFATc1 on osteoblast proliferation and differentiation, and on osteoblast activation of osteoclasts. Mice that expressed a constitutively nuclear NFATc1 variant (NFATc1nuc) showed rapid osteogenesis, likely mediated through Wnt signaling and not through Runx-2. Osteoclast formation was also promoted, independently of RANKL, but potentially involving the chemokine CCL8.
18. Fornoni, A., Cornacchia, F., Howard, G.A., Roos, B.A., Striker, G.E., and Striker, L.J. Cyclosporin A affects extracellular matrix synthesis and degradation by mouse MC3T3-E1 osteoblasts in vitro. Nephrol. Dial. Transplant. 16, 500-505 (2001).
19. McCauley, L.K., Rosol, T.J., and Capen, C.C. Effects of cyclosporin A on rat osteoblasts (ROS 17/2.8 cells) in vitro. Calcif. Tissue Int. 51, 291-297 (1992).
20. Sun L, Blair HC, Peng Y, Zaidi N, Adebanjo OA, Wu XB, Wu XY, Iqbal J, Epstein S, Abe E, Moonga BS, Zaidi M 2005 Calcineurin regulates bone formation by the osteoblast. Proc. Natl. Acad. Sci. U.S.A. 102, 17130-17135 (2005). Exogenous expression of calcineurin and the use of a calcineurin mutant in osteoblasts supported a role of the pathway in bone formation through the transcription factor Runx-2. This was direct evidence for an effect of calcineurin on osteoblast differentiation.
21. Komori, T., Yagi, H., Nomura, S. et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89, 755-764 (1997).
22. Nakashima, K., Zhou, X., Kunkel, G., Zhang, Z., Deng, J.M., Behringer, R.R., and de Crombrugghe, B. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108, 17-29 (2002).
23. Chen, D., Zhao, M., Mundy, G.R. Bone morphogenetic proteins. Growth Factors 22, 233-241 (2004).
24. Boyden, L.M., Mao, J., Belsky, J., Mitzner, L., Farhi, A., Mitnick, M.A., Wu, D., Insogna, K., and Lifton, R.P. 2002 High bone density due to a mutation in LDL-receptor-related protein 5. N. Engl. J. Med. 346, 1513-1521 (2002).
25. Gong, Y., Slee, R.B., Fukai, N. et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107, 513-523 (2001).
26. Yasuda, H., Shima, N., Nakagawa, N. et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U.S.A. 95, 3597-3602 (1998).
27. Rodino, M.A. and Shane, E. 1998 Osteoporosis after organ transplantation. Am. J. Med. 104, 459-469 (1998). This is a review which notes that the cyclosporine class of drugs have decreased transplant rejection and improved survival in the patients. The bone loss in patients receiving renal, heart, lung, bone marrow and liver transplants is reviewed. Although measurements of osteocalcin in the patients suggest that cyclosporine increases osteoblastic activity and bone formation, it is pointed out that renal damage from the drug could decrease the clearance of the osteocalcin.
28. Thiebaud, D., Krieg, M.A., Gillard-Berguer, D., Jacquet, A.F., Goy, J.J., and Burckhardt, P. Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation. Eur. J. Clin. Invest. 26, 549-555 (1995). This was a retrospective study on twenty-four patients who received cyclosporine A as part of the immunosuppressive regimen, which included tapered doses of glucocorticoid, after cardiac transplantation. Bone mineral density decreased, and there was a large increase in osteocalcin, a parameter of osteoblastic activity, indicating high bone turnover. Parathyroid hormone was also increased, and the authors conclude that the increase in bone turnover could have been due to either cyclosporine or secondary hyperparathyroidism.
29. Stewart, P.J., Green, O.C., and Stern, P.H. Cyclosporine A inhibits calcemic hormone-induced bone resorption in vitro. J. Bone Miner. Res. 1, 285-291 (1986).
30. Klaushofer, K., Hoffmann, O., Stewart, P.J., Czerwenka, E., Koller, K., Peterlik, M., and Stern, P.H. Cyclosporine A inhibits bone resorption in cultured neonatal mouse calvaria. J. Pharmacol. Exp. Ther. 243, 584-590 (1987).
31. Takayanagi, H., Kim, S., Koga, T. et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3, 889-901 (2002). This cutting-edge study on the role of NFAT in osteoclast differentiation demonstrated that RANKL selectively induced NFATc1 expression, that NFAT is essential for embryonic stem cells to differentiate into osteoclasts in response to RANKL, and that NFATc1 acts downstream of RANKL and may represent a "master switch" for the terminal differentiation of osteoclasts.
32. Hirotani, H., Touhy, N., Woo, J.T., Stern, P.H., and Clipstone, N.A. The calcineurin/NFAT signaling pathway regulates osteoclastogenesis in RAW 264.7 cells. J. Biol. Chem. 279, 13984-13992 (2004). This study used VIVIT, a specific calcineurin inhibitory peptide, to demonstrate that calcineurin is an essential downstream effector of RANKL-induced osteoclastic differentiation in the monocyte/macrophage cell line RAW 264.7. Expression of a constitutively active calcineurin-independent NFATc1 mutant in the RAW 264.7 cells resulted in their differentiation into a mature functional osteoclast phenotype.